Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.

Liver Int · 2025 · PMC12558666 · PMID 41144918

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In this 48‐week study, patients receiving subcutaneous semaglutide 0.4 mg daily achieved MASH resolution without worsening of fibrosis in 59% of cases compared to 17% in the placebo group, which was highly significant.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.